Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer

Oncology

Volumn 80, Issue 5-6, 2011, Pages 359-365

  Amarantidis, K ^a   Xenidis, N ^a   Chelis, L ^a   Chamalidou, E ^a   Dimopoulos, P ^a   Michailidis, P ^a   Tentes, A ^b   Deftereos, S ^a   Karanikas, M ^a   Karayiannakis, A ^a   Kakolyris, S ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b General Hospital of Didimoticho   (Greece)

Author keywords

Capecitabine; Docetaxel; Gastric cancer; Oxaliplatin; Phase II

Indexed keywords

CAPECITABINE; DOCETAXEL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONJUNCTIVITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PARESTHESIA; STOMACH NEOPLASMS; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79960867234     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330199     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. (Pubitemid 23182046)
3. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168. (Pubitemid 27112884)
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
5. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909. (Pubitemid 46630593)
6. Kim N, Park YS, Heo DS, et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
7. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657. (Pubitemid 30465650)
8. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
9. van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24; 4991-4997. (Pubitemid 46631401)
10. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
11. Kang Y-K KW, Shin DB, Chen J, et al: Capecitabine/cisplatin versus 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomized phase III noninferiority trial. Ann Oncol 2009; 20: 666-673.
12. Evans D, Miner T, Ianniti D, Akerman P, et al: Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: A phase II study. Cancer Investigation 2007; 25: 445-448. (Pubitemid 47450681)
13. Amarantidis K, Xenidis N, Chelis L, et al: A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Acta Oncologica 2010; 49: 245-251.
14. Gressett SM, Stanford BL, Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131-141. (Pubitemid 44696441)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 202-216.
16. Simon R: Optimal two stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10. (Pubitemid 19099520)
17. Ajani JA: Chemotherapy for gastric carcinoma: New and old options. Oncology (Huntingt) 1998; 12(suppl 7):44-47. (Pubitemid 28536408)
18. Ajani JA: Standard chemotherapy for gastric carcinoma: Is it a myth? J Clin Oncol 2000; 18: 4001-4003.
19. Wils JA, Klein HO, Wagener DJ, et al: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A stop ahead in the treatment of advanced gastric cancer - a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
20. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657. (Pubitemid 30465650)
21. Kelsen DD, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
22. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267. (Pubitemid 27020582)
23. Nadella P, Shapiro C, Otterson GA, et al: Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002; 20: 2616-2623. (Pubitemid 34575633)
24. Kurosumi M, Tabei T, Suemasu K, et al: Enhancement of immunohistochemical reactivity of thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000; 7: 945-948.
25. O'Shaughnessey J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823. (Pubitemid 34651510)
26. Burris H: Weekly schedules of docetaxel. Semin Oncol 1998; 6(suppl 2):21-23. (Pubitemid 28564179)
27. Hainsworth JD, Burris HA, Yardley DA, et al: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network Phase II Trial. J Clin Oncol 2001; 19: 3500-3505. (Pubitemid 32730087)
28. Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-1312. (Pubitemid 46606408)
29. Al-Batran SE, Hartmann JT, Probst S, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442.
30. Arnold D, Thuss-Patience P, Stein A, et al: Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ASCO 2010 #4099.
31. Shah MA, Shibata R, Stoller M, et al: Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol 2010; 28(suppl; abstr 4014):15s.
32. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27(suppl):18S.